Spots Global Cancer Trial Database for sti571
Every month we try and update this database with for sti571 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | NCT01735968 | 3rd Line GIST | ST571 + BYL719 | 18 Years - | Novartis | |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Head and Neck C... Squamous Cell C... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) | NCT00237172 | Gastrointestina... | Imatinib Mesyla... | 20 Years - 74 Years | Novartis | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Gleevec Study for Patients With Ovarian Cancer | NCT00510653 | Ovarian Cancer | Imatinib Mesyla... | 18 Years - | M.D. Anderson Cancer Center | |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | NCT00038649 | Myelogenous Leu... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | NCT00506779 | Uterine Cancer | Imatinib Mesyla... Paclitaxel | - | M.D. Anderson Cancer Center | |
| Late Chronic Phase Chronic Myelogenous Leukemia | NCT01092741 | Leukemia | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Late Chronic Phase Chronic Myelogenous Leukemia | NCT01092741 | Leukemia | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | NCT01735968 | 3rd Line GIST | ST571 + BYL719 | 18 Years - | Novartis | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | NCT00511303 | Chronic Myeloid... | STI571 | 18 Years - | University of Bologna | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha | NCT00171223 | Leukemia, Myelo... | STI571 | 18 Years - | Novartis | |
| Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | NCT00500110 | Prostate Cancer | Docetaxel Imatinib Mesyla... Leuprolide Goserelin Aceta... | - | M.D. Anderson Cancer Center | |
| Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | NCT00402766 | Mesothelioma | Cisplatin Imatinib Mesyla... Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | NCT00511303 | Chronic Myeloid... | STI571 | 18 Years - | University of Bologna | |
| A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | NCT01468688 | 3rd Line GIST | STI571 BKM120 | 18 Years - | Novartis | |
| A Study of Nilotinib Versus Imatinib in GIST Patients | NCT00785785 | Gastrointestina... | Nilotinib (AMN1... imatinib (STI57... | 18 Years - | Novartis | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
